RemeGen Invests in Wealth Management Products

MT Newswires Live05-15

RemeGen (HKG:9995, SHA:688331) said it invested in various wealth management products offered by Huatai Securities, according to a Friday filing with the Hong Kong bourse.

The biopharmaceutical company invested 60 million yuan in a fixed-income product that invests in debt assets, 75 million yuan in another fixed-income product that covers liquid financial instrument, and a further 102 million yuan in a fixed-income product tied to financial products and cash-type assets.

The company also invested 216 million yuan in a ten-year product that will be invested in financial products and cash-type assets.

The firm said the products will help "revitalize idle funds."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment